FMO5 and Hyperglycemia: In addition, metformin or liraglutide inhibits hyperglycemia-induced ROS production though downregulation of PKC-dependent NADPH oxidase in human ECs (Batchuluun et al., 2014), which partly elucidates their athero-protective effects.